The clinical landscape of HDAC inhibitors

Ganesan, A. ORCID: https://orcid.org/0000-0003-4862-7999 (2021) The clinical landscape of HDAC inhibitors. In: Medical Epigenetics. Elsevier, pp. 885-899. ISBN 9780128239285

Full text not available from this repository. (Request a copy)

Abstract

There are eleven human isoforms of the zinc-dependent histone deacetylases (HDACs). These proteins are involved in the removal of acetyl and fatty acid acyl chains from polyamines and lysine residues in proteins. Of particular importance is histone deacetylation, the inhibition of which leads to transcriptional activation. Over the last two decades, many small molecule HDAC inhibitors have reached clinical development, with five approved drugs to date in oncology. This chapter reviews the recent progress in HDAC inhibitor therapy and discusses how isoform selectivity is central to exploiting the therapeutic potential of these compounds in cancer as well as other indications.

Item Type:	Book Section
Uncontrolled Keywords:	amidohydrolases,clinical trials,enzyme inhibitors,epigenetics,gene transcription,histone deacetylases,metalloenzymes,medicine(all),biochemistry, genetics and molecular biology(all),sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/2700
Faculty \ School:	Faculty of Science > School of Pharmacy
UEA Research Groups:	Faculty of Science > Research Groups > Chemical Biology and Medicinal Chemistry (former - to 2021)
Related URLs:	http://www.scopus.com/inward/record.url?... https://linkinghub.elsevier.com/retrieve...
Depositing User:	LivePure Connector
Date Deposited:	16 Sep 2021 08:55
Last Modified:	22 Oct 2022 23:55
URI:	https://ueaeprints.uea.ac.uk/id/eprint/81411
DOI:	10.1016/B978-0-12-823928-5.00036-0

Actions (login required)

View Item